This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Schmidt, M. E. Search for Related Content Social Bookmarking                         What's this?

The Future of Imaging in Drug Discovery

Neuroscience Therapeutic Area, Lilly Research Laboratories, Lilly Corporate Center, DC: 1730, Indianapolis, Indiana 46285, mschmidt{at}lilly.com

The number of new chemical entities being registered by drug companies each year is declining, while at the same time, the number of new compounds, and thereby potential therapeutics, is increasing at an exponential rate. The need to demonstrate the safety, efficacy, and the "value" of these new compounds to a sophisticated pharmaceutical market, driven in turn by the forces of healthcare economics, make drug development difficult, resulting in a very lengthy and complex series of steps in the development of a drug. Many aspects of clinical pharmacology are more art than science, and detecting pharmacological effects at the level of living integrated systems is difficult. These challenges are most evident when developing new therapeutics for neuropsychiatric illnesses. We may at last be entering a postmonoamine era, exemplified by compounds such as NK-1 antagonists and metatropic glutamate receptor agonists. Such developments hold significant promise for the treatment of severe mental illness, while at the same time being confronted with completely unknown clinical pharmacologies. Functional imaging may not only be useful for the development of new CNS compounds, but it may in fact be essential for helping to define their clinical pharmacology. Several examples will be addressed that highlight the utility of functional imaging in the development of potentially new CNS drugs.

Key Words: drug discovery • functional imaging • ligands • metabolic imaging • positron emission tomography

Journal of Pharmacy Practice, Vol. 14, No. 5, 427-434 (2001)
DOI: 10.1177/089719001129040766


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?